WuXi AppTec Co., Ltd. Share Price

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 03:30:00 22/05/2024 am IST 5-day change 1st Jan Change
44.12 CNY +0.94% Intraday chart for WuXi AppTec Co., Ltd. -2.43% -39.36%

Financials

Sales 2024 * 39.52B 5.46B 454B Sales 2025 * 46.17B 6.38B 531B Capitalization 125B 17.32B 1,442B
Net income 2024 * 9.7B 1.34B 112B Net income 2025 * 11.54B 1.59B 133B EV / Sales 2024 * 2.93 x
Net cash position 2024 * 11.33B 1.56B 130B Net cash position 2025 * 16.39B 2.26B 188B EV / Sales 2025 * 2.47 x
P/E ratio 2024 *
13.2 x
P/E ratio 2025 *
11.2 x
Employees 41,116
Yield 2024 *
2.28%
Yield 2025 *
2.42%
Free-Float 66.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.94%
1 week-2.43%
Current month+1.03%
1 month+4.80%
3 months-18.46%
6 months-47.62%
Current year-39.36%
More quotes
1 week
43.50
Extreme 43.5
45.75
1 month
41.30
Extreme 41.3
48.68
Current year
41.17
Extreme 41.17
75.38
1 year
41.17
Extreme 41.17
93.56
3 years
41.17
Extreme 41.17
172.49
5 years
32.58
Extreme 32.5808
172.49
10 years
11.02
Extreme 11.0204
172.49
More quotes
Managers TitleAgeSince
Founder 54 01/00/01
Chief Executive Officer 56 01/00/01
Chief Executive Officer 55 01/15/01
Members of the board TitleAgeSince
Chief Investment Officer 61 01/07/01
Chief Executive Officer 56 01/00/01
Founder 54 01/00/01
More insiders
Date Price Change Volume
22/24/22 44.12 +0.94% 48,207,700
21/24/21 43.71 -2.21% 66,921,740
20/24/20 44.7 -0.45% 56,243,140
17/24/17 44.9 -1.49% 69,469,580
16/24/16 45.58 +0.80% 96,750,800

End-of-day quote Shanghai S.E., May 22, 2024

More quotes
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
44.12 CNY
Average target price
68.82 CNY
Spread / Average Target
+55.99%
Consensus
  1. Stock Market
  2. Equities
  3. 603259 Stock